Cellectis (CLLS) Exchange Rate Effect (2015 - 2026)
Cellectis (CLLS) posted quarterly Exchange Rate Effect of -$217000.0 for Q1 2026, down 115.37% year-over-year from $1.4 million in Q1 2025, and down 116.19% quarter-over-quarter from $1.3 million in Q4 2025.
Powered by 
Analysis
Cellectis (CLLS) Exchange Rate Effect (2015 - 2026) Analysis & Trends
Cellectis' Exchange Rate Effect history runs 12 years deep, the most recent figure standing at -$217000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 115.37% year-over-year to -$217000.0; the TTM figure through Mar 2026 stood at $2.3 million (up 314.26% YoY), while the FY2025 annual figure was $3.9 million, up 242.73% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$217000.0, down from $1.3 million in the prior quarter.
- The five-year high for Exchange Rate Effect was $2.0 million in Q4 2022, with the low at -$2.9 million in Q2 2022.
- The 5-year median for Exchange Rate Effect is -$217000.0 (2026), against an average of -$89235.3.
- The sharpest annual moves came in 2022 and 2024: Exchange Rate Effect sank 798.33% in 2022, then soared 1164.12% in 2024.
- Cellectis' Exchange Rate Effect stood at $2.0 million in 2022, then retreated by 14.36% to $1.7 million in 2023, then plunged by 220.46% to -$2.1 million in 2024, then surged by 165.21% to $1.3 million in 2025, then sank by 116.19% to -$217000.0 in 2026.
- Business Quant data shows CLLS's Exchange Rate Effect at -$217000.0 in Q1 2026, $1.3 million in Q4 2025, and $1.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -427,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -427,000.00 |
| Mar 31, 2026 | -217,000.00 |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | -529,000.00 |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | -2.06 Mn |
| Sep 30, 2024 | -2.24 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | -267,000.00 |
| Dec 31, 2023 | 1.71 Mn |
| Sep 30, 2023 | -1.32 Mn |
| Jun 30, 2023 | -170,000.00 |
| Mar 31, 2023 | 669,000.00 |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | -1.57 Mn |
| Jun 30, 2022 | -2.93 Mn |
| Mar 31, 2022 | -852,000.00 |
| Dec 31, 2021 | -2.37 Mn |
| Sep 30, 2021 | -950,000.00 |